Recent Finacing
Recent Raise
Persevere Therapeutics is a clinical-stage oncology company developing misetionamide, a first-in-class dual inhibitor of c-MYC and NFκB for hard-to-treat cancers such as platinum-resistant ovarian cancer.
Focus Areas
Funding round
See the team members at Persevere Therapeutics.
